[EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ATHÉROSCLÉROTIQUES À L'AIDE DE MODULATEURS DE PDE4
申请人:CELGENE CORP
公开号:WO2015175956A1
公开(公告)日:2015-11-19
Provided herein are methods of treating, preventing or managing atherosclerosis by administering a PDE4 modulator. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods are also provided.
Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
申请人:Zeldis B. Jerome
公开号:US20060004054A1
公开(公告)日:2006-01-05
Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α(TNF-α) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.
Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids
申请人:——
公开号:US20010049371A1
公开(公告)日:2001-12-06
Imido and amido substituted alkanohydroxamic acids reduce the levels of TNF&agr; and inhibit phosphodiesterase in a mammal. A typical embodiment is 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide.
Substituted alkanohydroxamic acids and method of reducing TNFalpha levels
申请人:——
公开号:US20040006096A1
公开(公告)日:2004-01-08
Imido and Amido substituted alkanohydroxamic acids reduce the levels of TNFa and inhibit phosphodiesterase in a mammal. A typical embodiment is 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide.
Substituted alkanohydroxamic acids and method of reducing TNFα levels
申请人:——
公开号:US07091356B2
公开(公告)日:2006-08-15
Imido and Amido substituted alkanohydroxamic acids reduce the levels of TNFa and inhibit phosphodiesterase in a mammal. A typical embodiment is 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide.